Comprehensive Cell Solutions

What Comprehensive Cell Solutions does

Comprehensive Cell Solutions (CCS) is a business division of New York Blood Center Enterprises (NYBCe), a 501(c)(3) nonprofit founded in 1964 and headquartered in New York. CCS provides end-to-end development and manufacturing services for cell and gene therapy developers, operating as a contract development and manufacturing organization (CDMO) with Good Manufacturing Practice (GMP) and Good Tissue Practice (GTP) compliant capabilities. Its service portfolio covers cell sourcing and apheresis, GMP/GTP manufacturing, cryopreservation, process development, analytical development, storage and logistics, and quality control and regulatory support, addressing capacity constraints for early-stage developers, hospital treatment centers, and pharmaceutical organizations.

The underlying technology is a physical manufacturing and biologics-handling platform rather than a software or data product. It relies on apheresis-based cell collection, controlled-environment manufacturing, cryogenic storage, and analytical/QC testing infrastructure that NYBCe has built over six decades as one of the largest independent community-based blood centers in the U.S. CCS is structurally advantaged by access to the Lindsley F. Kimball Research Institute (LFKRI, established 1974) and the broader NYBCe portfolio, which includes eight regional blood center divisions, the NYBC Ventures fund, and the NYBC RX specialty pharmacy. The division operates with 11-50 employees and runs as a non-listed, nonprofit-owned entity.

Commercially, CCS pursues an enterprise B2B go-to-market via direct sales and business development, with customized, quote-based contracts across development through commercial manufacturing. Revenue is not separately disclosed because NYBCe is a 501(c)(3) nonprofit, and no pricing, contract minimums, customer logos, or backlog figures are publicly available. Customer concentration, ARR, and churn metrics are therefore not estimable from public data, and customer acquisition is described as relationship-driven through NYBCe's enterprise channels.

Name

Comprehensive Cell Solutions

Legal name

New York Blood Center, Inc.

Website

https://nybce.org

Company type

Private

Founded year

1964

Operating status

Operating

Headcount range

11–50 employees

Short description

Comprehensive Cell Solutions is a NYBCe division providing end-to-end GMP/GTP cell and gene therapy development and manufacturing services, including apheresis, cryopreservation, process and analytical development, and regulatory support for early-stage developers, hospitals, and pharma.

Ownership category

akta.pro rank

Product category

Cell and Gene Therapy Contract Development and Manufacturing

NAICS

Scientific Research and Development Services (5417), Medical and Diagnostic Laboratories (62151)

SIC

Services-Medical Laboratories (8071), Services-Health Services (8000)

akta.pro primary industry

Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish) (HLAAABAG)

akta.pro secondary industry

Cell & Gene Therapy Chain-of-Identity/Chain-of-Custody Logistics (HLAGAMAE)

Keywords

• Cell therapy manufacturing
• Gene therapy development
• GMP contract manufacturing
• Apheresis cell sourcing
• Cryopreservation services

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Comprehensive Cell Solutions (CCS) provides end-to-end development and manufacturing services for cell and gene therapy products. Offerings include cell sourcing and apheresis, GMP/GTP-compliant manufacturing, cryopreservation, process development, analytical development, storage and logistics, and quality control and regulatory support for early-stage developers, hospital treatment centers, and pharmaceutical organizations.

Product overview

Comprehensive Cell Solutions (CCS) is a cell and gene therapy-focused development and manufacturing organization that provides end-to-end services for early-stage developers, hospital treatment centers, and pharmaceutical organizations. The service portfolio includes Cell Sourcing and Apheresis, GMP/GTP Manufacturing, Cryopreservation, Process Development, Analytical Development, Storage & Logistics, and Quality Control & Regulatory services. CCS operates as a business unit within New York Blood Center Enterprises, leveraging the organization's infrastructure and expertise in blood and cellular therapies.

Differentiator

Problem solved

Functional benefit

Products and services

• Cell Sourcing and Apheresis
• GMP/GTP Manufacturing
• Cryopreservation
• Process Development
• Analytical Development
• Storage and Logistics
• Quality Control and Regulatory

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Lonza Cell & Gene Technologies: Lonza is one of the world's largest CDMOs with a dedicated Cell & Gene Technologies business offering process development, GMP manufacturing, and analytical services for cell and gene therapy developers. Directly comparable in service scope to CCS but vastly larger in scale, geographic reach, and capital base.
• Catalent Cell & Gene Therapy: Catalent is a major global CDMO with a Cell & Gene Therapy division providing development, manufacturing, fill-finish, and analytical services for autologous and allogeneic cell therapies. Comparable end-to-end service offering to CCS with substantially greater commercial capacity and biopharma relationships.
• Charles River Laboratories: Charles River provides cell therapy CDMO services including process development, GMP manufacturing, and analytical testing through its Cell & Gene Therapy CDMO business. Comparable as a services-led CDMO serving the same early-stage to commercial-stage cell therapy developer market as CCS.
• Thermo Fisher Scientific (Pharma Services): Thermo Fisher's Pharma Services division (including the Patheon CDMO business) provides cell therapy development and manufacturing services for biopharma clients. Comparable as a large, diversified CDMO with overlapping cell therapy service offerings to CCS.

Emerging players

• Cellares: Cellares is developing automated, closed-system manufacturing platforms (Cell Shuttle) for cell therapies, combining automation IP with CDMO services. Directly relevant as a cell therapy manufacturing competitor, though differentiated by a technology-platform rather than services-led approach.
• Vineti: Vineti provides a cell therapy orchestration and chain-of-identity/chain-of-custody software platform plus related services for advanced therapy developers. Comparable to CCS in addressing the cell therapy workflow and supply chain, though focused on software/coordination rather than physical manufacturing.
• Resilience: Resilience is a technology-focused biomanufacturing company providing CDMO services across cell therapies, biologics, and advanced modalities. Comparable as a newer-entrant cell therapy CDMO competing for the same biopharma developer relationships as CCS.

Direct peers

• Cryoport Systems: Cryoport provides temperature-controlled cold chain logistics and chain-of-custody solutions for cell and gene therapies, including cryopreservation, storage, and shipping. Directly comparable to CCS's Storage & Logistics and Cryopreservation service lines, and a common partner/substitute for cell therapy developers.
• Aldevron: Aldevron (now part of Danaher) is a CDMO specializing in plasmid DNA, mRNA, and protein production for cell and gene therapy developers. Comparable as a cell and gene therapy-focused CDMO serving the same developer customer base as CCS.
• Be The Match BioTherapies: Be The Match BioTherapies is the cell therapy services arm of the National Marrow Donor Program, providing apheresis network access, cell sourcing, and manufacturing support services for cell therapy developers. Highly comparable to CCS as a nonprofit-affiliated cell therapy services organization with a differentiated donor/cell sourcing network.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/comprehensive-cell-solutions

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Comprehensive Cell Solutions